Neurology Today in 5
Medical
Joseph E. Safdieh, MD, FAAN, Editor-in-Chief of Neurology Today highlights the most noteworthy and newsworthy neurology stories in the issue.
Location:
United States
Description:
Joseph E. Safdieh, MD, FAAN, Editor-in-Chief of Neurology Today highlights the most noteworthy and newsworthy neurology stories in the issue.
Language:
English
Website:
http://www.neurotodayonline.com
Episodes
Generative AI for personal statements, Match Day and neurology, AHS statement on CGRP-targeting therapies
5/1/2024
Neurology Today Editor-in-Chief Joseph E. Safdieh, MD, FAAN, highlights new articles that discuss program directors’ response to the use of generative AI for personal statements, the good news for neurology based on the 2024 Match Day, and the AHS statement on CGRP-targeting therapies as a game changer for migraine treatment.
Duration:00:04:48
ME/CFS and long COVID; negative outcomes for ALS drug; donanemab
4/17/2024
Neurology Today Editor-in-Chief Joseph E. Safdieh,MD, FAAN, highlights new research that explores an association between myalgic encephalomyelitis/chronic fatigue and long COVID; negative phase 3 findings on AMX0035 for ALS, and the pending approval of donanemab for Alzheimer’s disease.
Duration:00:04:31
BTK inhibitors for MS, lecanemab, neurologic adverse effects and COVID vaccine
4/3/2024
Neurology Today Editor-in-Chief Joseph E. Safdieh,MD, FAAN, highlights new research that casts doubt on the future of BTK inhibitors for MS, an assessment of the cost-effectiveness of lecanemab, and findings that COVID vaccines are not significantly associated with adverse neurologic events.
Duration:00:04:24
SARS-CoV-2 and dopamine neurons, valproate risks for men, neurologists on locum tenens
3/20/2024
Neurology Today Editor-in-Chief Joseph E. Safdieh, MD, FAAN, highlights new stories reporting on the impact of SARS-CoV2 on dopamine neurons, a European Medicines Agency warning about valproate risks for men, and neurologists on the pros and cons of working locum tenens.
Duration:00:04:38
AI and 911 stroke detection, iatrogenic Alzheimer’s and human growth hormone, seizure dogs and refractory epilepsy
3/6/2024
Neurology Today Editor-in-Chief Joseph E. Safdieh, MD, FAAN, highlights new stories reporting on the use of AI in EMS systems for stroke detection, the association between human growth hormone and iatrogenic Alzheimer’s, and seizure dogs for refractory epilepsy.
Duration:00:04:38
Biomarker for migraine; posterior cortical atrophy gene therapy for neuromuscular disorders
2/12/2024
Neurology Today Editor-in-chief Joseph E. Safdieh, MD, FAAN, discusses a new study showing retinal vascular perfusion as a migraine biomarker, clinical and pathophysiological correlates of posterior cortical atrophy, and advances in gene therapies for neuromuscular disorders.
Duration:00:04:30
Cerebral amyloid angiopathy and nontraumatic subdural hemorrhage, AI for neurology boards, weight loss drugs and neurologic conditions
1/25/2024
Neurology Today Editor-in-chief Joseph E. Safdieh, MD, FAAN, discusses new studies showing the cerebral amyloid angiopathy as a risk factor for nontraumatic subdural hemorrhage, AI beats humans in neurology-like boards, and the impact of popular weight loss drugs on neurologic conditions.
Duration:00:04:39
Rising incidence of Creutzfeldt-Jakob disease, therapy for prodromal migraine, neurotrauma of blast injury
1/16/2024
Neurology Today Editor-in-chief Joseph E. Safdieh, MD, FAAN, discusses new studies showing the rising incidence of Creutzfeldt-Jakob disease, an effective therapy for prodromal migaine, and neuroinflammation in military personnel exposed to blast injury.
Duration:00:04:18
DBS and cognition in severe TBI, in utero exposure to antiseizure drugs, best advances of 2023
1/2/2024
Neurology Today Editor-in-chief Joseph E. Safdieh, MD, FAAN, discusses new studies on the impact of deep brain stimulation on cognition in severe traumatic brain injury and how adaptive functioning is impacted in children exposed to antiseizure drugs in utero, and the editorial board’s picks for the best advances of 2023.
Duration:00:04:08
Parkinson’s and suicide risk; biomarkers and underrepresentation in Alzheimer’s trials, immune system changes in ALS and Parkinson’s.
12/21/2023
Neurology Today Editor-in-chief Joseph E. Safdieh, MD, FAAN, discusses new studies showing double the suicide risk among Parkinson’s patients; underrepresentation of non-White people in Alzheimer’s trial related to biomarker eligibility; early immune systems changes may play early role in ALS and Parkinson's.
Duration:00:04:36
Serotonin and long COVID, Afib detected 3 years after stroke, Medicare on PET amyloid scans
12/7/2023
Neurology Today Editor-in-chief Joseph E. Safdieh, MD, FAAN, discusses new studies showing serotonin depletion associated with long COVID; implantable cardiac monitors detect Afib 3 years post-stroke; and what Medicare’s decision to cover PET amyloid scans means for neurologists.
Duration:00:04:43
A promising drug for refractory epilepsy; adverse childhood events and headache disorders; pathological engulfment by microglia in dementia.
11/16/2023
Neurology Today Editor-in-chief Joseph E. Safdieh, MD, FAAN, discusses new studies on a promising potassium channel opener for refractory epilepsy; the impact of adverse childhood events in headache disorders; and excessive engulfment by microglia/astroctyes in dementia.
Duration:00:04:49
Blood transfusions and spontaneous intracerebral hemorrhages, long distance travel to neurologists, biomarkers for Parkinson’s disease
11/2/2023
Neurology Today Editor-in-chief Joseph E. Safdieh, MD, FAAN, discusses new research on the risk of spontaneous intracerebral hemorrhages after blood transfusions; the burden of long distance travel to see neurologists; and two promising biomarkers for early diagnosis of Parkinson’s disease.
Duration:00:04:43
Blood pressure and endovascular therapy, cutbacks in neurology CME, blood test for Alzheimer’s
10/19/2023
Neurology Today Editor-in-chief Joseph E. Safdieh, MD, FAAN, discusses new research on blood pressure targets for stroke after endovascular therapy, changing policies on CME, and a direct-to-consumer blood test for Alzheimer’s disease.
Duration:00:04:47
Football and Parkinson’s, deep brain stimulation for stroke recovery, neuroprostheses for anarthric patients
10/5/2023
Neurology Today Editor-in-chief Joseph E. Safdieh, MD, FAAN, discusses new research on football and the risk for Parkinson’s disease, the potential of deep brain stimulation for recovery from stroke, and neuroprostheses for patients with anarthria.
Duration:00:04:47
Medicare coverage of carotid stenting, disparities in vulnerable neuro-oncology patients, optical EMG for neuromuscular disorders.
9/21/2023
Neurology Today Editor-in-chief Joseph E. Safdieh, MD, FAAN, discusses the Medicare’s proposed coverage of carotid stenting in asymptomatic patients,neuro-oncologists’ perspectives on a federal initiative to target persistent poverty in vulnerable patients, and the technological promise of a new optical EMG for neuromuscular disorders.
Duration:00:05:12
Endovascular treatment and intracranial tumors; guideline on IVIG use for neuromuscular disorders, pros and cons of donanemab.
9/7/2023
Neurology Today Editor-in-chief Joseph E. Safdieh, MD, FAAN, discusses research that assesses the safety of endovascular treatment post-stroke for people with intracranial tumors, the AANEM guideline on IVIG use for neuromuscular disorders, and the latest data on donanemab.
Duration:00:05:27
Oral health and cognitive decline; managing first-ever sleep seizures; growth of concierge neurology.
8/17/2023
Neurology Today Editor-in-chief Joseph E. Safdieh, MD, FAAN, discusses studies that associate poor oral health and risk for cognitive decline and how to manage first-ever sleep seizures that recur as well as the growth of concierge neurology.
Duration:00:04:56
Gene variants and MS severity, AI and EEG reads, neuroprotective agent for ischemic stroke
8/3/2023
Neurology Today Editor-in-chief Joseph E. Safdieh, MD, FAAN, discusses studies that identify gene variants associated with MS severity/progression, an AI program that read EEGs accurately, and butylphthalide as a promising neuroprotective agent for ischemic stroke.
Duration:00:05:43
Antigen tolerance in mouse MS model, epileptiform activity and ICU outcomes, agent slows gliomas.
7/20/2023
Neurology Today Editor-in-chief Joseph E. Safdieh, MD, FAAN, discusses a novel therapeutic approach that induced antigen tolerance in an MS mouse model, the association between epileptiform activity and ICU outcomes, and an agent, vorasidenib, that slows low-grade gliomas.
Duration:00:05:12